Cancer Cachexia Market Companies
- AbbVie Inc.
- Actimed Therapeutics
- Aeterna Zentaris Inc.
- ANI Pharmaceuticals Inc.
- Aphios Corporation
- Aveo Pharmaceuticals Inc.
- Bristol-Myers Squibb Company
- Helsinn Group
- Hikma Pharmaceuticals PLC
- Merck & Co. Inc.
- Mylan N.V.
- Pfizer Inc.
- TCI Peptide Therapeutics
- Teva Pharmaceutical Industries Ltd.
Recent News:
- Meta Fines, a pharmaceutical repositioning company, said in February 2024 that it had signed a licensing agreement with BMI Korea for cancer cachexia treatment. According to the deal, BMI Korea will co-own ASCA101_CC's global technology transfer rights with Meta Fines. It will have the option to license the product in specified regions, including Korea and Southeast Asia. BMI Korea will pay Meta Fines 2 billion won ($1.51 million) up front, with the remaining 46 billion won paid in tiered milestones. ASCA101_CC is a pipeline for cancer cachexia.
- Pfizer expects cancer treatments to help it regain footing in February 2024, following a challenging year marked by a rapid decline in its Covid business. Following a more than 40% drop in its stock price in 2023, the pharmaceutical company has been striving to boost investor interest. Pfizer claims its joint drug pipeline with cancer startup Seagen could yield at least eight blockbuster therapies by 2030. With Seagen, Pfizer expects its medical pipeline to produce at least eight blockbuster medications by 2030, up from five. However, the company did not disclose which medicines it thinks have such promise.